Benefit/risk for adjuvant breast cancer therapy with tamoxifen or aromatase inhibitor use by age, and race/ethnicity-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Benefit/risk for adjuvant breast cancer therapy with tamoxifen or aromatase inhibitor use by age, and race/ethnicity

Published:2015-11-24 Issue:3 Volume:154 Page:609-616
ISSN:0167-6806
Container-title:Breast Cancer Research and Treatment
language:en
Short-container-title:Breast Cancer Res Treat

Author:

Chlebowski R. T.,Haque R.,Hedlin H.,Col N.,Paskett E.,Manson J. E.,Kubo J. T.,Johnson K. C.,Wactawski-Wende J.,Pan K.,Anderson G.

Funder

Kaiser Foundation Research Institute

Publisher

Springer Science and Business Media LLC

Subject

Cancer Research,Oncology

Link

http://link.springer.com/content/pdf/10.1007/s10549-015-3647-1.pdf

Reference31 articles.

1. Early Breast Cancer Trialists’ Collaborative Group (EBCTCG) (2015) Aromatase inhibitors versus tamoxifen in early breast cancer: patient-level meta-analysis of the randomized trials. Lancet 386:1341–1352

2. Braithwaite RS, Chlebowski RT, Lau J et al (2003) Meta-analysis of vascular and neoplastic events associated with tamoxifen. J Gen Intern Med 18:937–947

3. Cuppone F, Bria E, Verma S et al (2008) Do adjuvant aromatase inhibitors increase the cardiovascular risk in postmenopausal women with early breast cancer? Meta-analysis of randomized trails. Cancer 112:260–267

4. Amir E, Seruga B, Niraula S et al (2011) Toxicity of adjuvant endocrine therapy in postmenopausal breast cancer patients: a systemic review and meta-analysis. J Natl Cancer Inst 103:1299–1309

5. Dowsett M, Cuzick J, Ingle J et al (2010) Meta-analysis of breast cancer outcomes in adjuvant trials of aromatase inhibitors versus tamoxifen. J Clin Oncol 28:509–518

Cited by 18 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Systemic therapy and prognosis of older patients with stage II/III breast cancer: A large-scale analysis of the Japanese Breast Cancer Registry;European Journal of Cancer;2021-09

2. Effects on the skeleton from medications used to treat nonskeletal disorders;Marcus and Feldman's Osteoporosis;2021

3. Appraising the quality of meta-analysis for breast cancer treatment in the adjuvant setting: A systematic review;Cancer Treatment and Research Communications;2021

4. Androgens, oestrogens and endometrium: a fine balance between perfection and pathology;Journal of Endocrinology;2020-09

5. All-Cause and Cardiovascular Disease Mortality Among Breast Cancer Survivors in CLUE II, a Long-Standing Community-Based Cohort;JNCI: Journal of the National Cancer Institute;2020-07-07

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3